Aeglea BioTherapeutics, Inc. announced on October 6, 2023, the Board of Directors of Aeglea BioTherapeutics, Inc. appointed Dr. Cameron Turtle, the Company?s Chief Operating Officer, as the principal executive officer of the Company, effective as of the same day. Dr. Turtle joined the Company as its Chief Operating Officer in June 2023. Dr. Turtle is an experienced leader in building, financing, and shaping biopharma organizations from preclinical development to late-stage clinical trials and commercialization.

Prior to joining the Company, Dr. Turtle was an advisor to Spyre Therapeutics, Inc. (?Spyre?) from May 2023 to June 2023. Previously, he served as Venture Partner at Foresite Labs, a life sciences investment firm, from July 2022 to May 2023; Chief Strategy Officer of BridgeBio Pharma, from January 2021 to April 2022; and Chief Business Officer of Eidos Therapeutics, from November 2018 to January 2021, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining Eidos, he was a consultant at McKinsey & Company, where he worked with pharmaceutical and medical device companies on topics including M&A, growth strategy, clinical trial strategy, and sales force optimization.

Dr. Turtle received his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular Medicine from the University of Oxford, St. John?s College.

He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes 30 Under 30, San Francisco Business Times 40 Under 40, and the Biocom Life Sciences Catalyst Award.